Based on the promising result, the Food and Drug Administration (FDA) granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation, Wilmington, DE, USA) for the treatment of patients with previously treated cholangiocarcinoma with FGFR2 fusion or other rearrangements in April 2020 [35]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.